BBI 825
Alternative Names: BBI-825Latest Information Update: 07 Sep 2026
At a glance
- Originator Boundless Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action Ribonucleotide reductase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 22 Apr 2026 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR 2026)
- 20 Jan 2026 Boundless Bio terminates a phase-I/II POTENTIATE trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) due to strategic portfolio prioritization by the company (NCT05827614)
- 22 Oct 2025 Pharmacodynamics data from a preclinical study in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)